Clinical Trials Arena on MSN2d
Seismic Therapeutic doses first healthy participant cohort in Phase I trial of S-1117
US-based biotechnology company Seismic Therapeutic has dosed the initial cohort of healthy participants in a randomised Phase ...
Seismic Therapeutic Doses First Cohort in Phase 1 Clinical Trial of S‑1117, a Novel Pan‑IgG Protease Therapy for Antibody-Mediated Diseases
Seismic Therapeutic, Inc., the machine learning immunology company, today announced the dosing of the first healthy subject ...
pharmaphorum1y
Seismic shakes up $121m for AI-designed immunology drugs
According to Jo Viney – Seismic’s founder, president, and chief executive, who was formerly head of R&D at Pandion, which was acquired by MSD/Merck & Co in 2021 – said that the new funding ...